DIANA I BRIXNER portrait
  • Member of Pharmacotherapy Outcomes Research Center, Pharmacotherapy
  • Associate Member, HCI Cancer Control and Population Sciences Research Program, Huntsman Cancer Institute
  • President of International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
  • Professor, Pharmacotherapy
  • Past President Academy of Managed Care Pharmacy
  • Adjunct Professor, Pharmacotherapy
  • Adjunct Professor, Pediatrics
  • Professor, Pharmacotherapy

Education

  • B.S., 1982, Pharmacy, University of Rhode Island
  • Ph.D., 1987, Medicinal Chemistry, University of Utah
  • Modeling Approaches for Health Technology Assessment Certificate, 2010, University of Health Sciences, Hall in Tirol, Austria
  • Clinical Epidemiology Certificate, 2013, University of Health Sciences, Hall in Tirol, Austria
  • Introduction to Health Technology Assessment Certificate, 2015, University of Health Science, Hall in Tirol, Austria

Biography

Dr. Diana Brixner is currently Professor in the Department of Pharmacotherapy and serves as the Executive Director of the Pharmacotherapy Outcomes Research Center at the University of Utah in Salt Lake City, UT. She holds two adjunct positions in the School of Medicine in the Department of Population Health Sciences and Department of Pediatrics. She is a member of the Huntsman Cancer Institute Cancer Control and Population Sciences and the Center for Genomic Medicine. Prior to her academic appointment in 2002 she worked both in the biotech (NeoRx) and pharmaceutical (SmithKline Beecham, Novartis) industry focused on value assessment of their technologies in the early years of the field. Dr. Brixner was a Past President for both the Academy of Managed Care Pharmacy (AMCP) and International Society of Pharmacoeconomics and Outcomes Research (ISPOR). She was recently a oneyear Scholar-in-Residence for the Academy of Managed Care Pharmacy. She serves on the scientific advisory board of Lumanity and is also a member of the board of the International Market Access Society.